comprehensive -WSS

comprehensive

author：comprehensive 2025-09-03 12:11:02 - browse：41

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Why health records don't always know when patients are dead

focus

WSS

What AAP's gender

Why health records don't always know when patients are dead

Violet CEO on training clinicians to promote more inclusive care

What AAP's gender

HCA sued by state AG for quality issues at Mission Health

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

entertainment

comprehensive

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

After affirmative action ruling, medical educators look to 'holistic review'

Drinking less cuts risk of oral cavity, esophageal cancer: Report

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC advisory panel says seniors 'may' get RSV vaccine

Anesthesiologist group: stop taking Ozempic before surgery

Departing Stanford president retracts two papers

In age of alternative facts, a scholarly course on calling out crap

Appeals court upholds limits to abortion pill

focus

Radiation, mainstay of cancer treatment, begins a fade

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Albert Bourla of Pfizer: worst biopharma CEO of 2023

SNAP should offer more nutrition education

Drug firms test therapies to halt Alzheimer’s before symptoms arise

What do new weight loss drugs mean for bariatric surgery?

knowledge

focus

focus

hotspot